Wealth of opportunity - the C1 domain as a target for drug development.
about
The Novel PKCθ from Benchtop to ClinicIdentification of the activator-binding residues in the second cysteine-rich regulatory domain of protein kinase Cθ (PKCθ)Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?Protein kinase C: poised to signalEmerging methodologies to investigate lipid-protein interactionsC1 Domain-targeted isophthalate derivatives induce cell elongation and cell cycle arrest in HeLa cellsp23/Tmp21 associates with protein kinase Cdelta (PKCdelta) and modulates its apoptotic function.Binding of curcumin and its long chain derivatives to the activator binding domain of novel protein kinase C.Probing the determinants of diacylglycerol binding affinity in the C1B domain of protein kinase Cα.Charge density influences C1 domain ligand affinity and membrane interactionsMolecular systems pharmacology: isoelectric focusing signature of protein kinase Cδ provides an integrated measure of its modulation in response to ligandsNeuronal porosome lipidomeThe bryostatin 1 A-ring acetate is not the critical determinant for antagonism of phorbol ester-induced biological responses.Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.Neristatin 1 provides critical insight into bryostatin 1 structure-function relationshipsSome phorbol esters might partially resemble bryostatin 1 in their actions on LNCaP prostate cancer cells and U937 leukemia cellsMolecular basis for failure of "atypical" C1 domain of Vav1 to bind diacylglycerol/phorbol ester.TRPV1 activation is not an all-or-none event: TRPV1 partial agonism/antagonism and its regulatory modulation.PKC in Regenerative Therapy: New Insights for Old Targets.Diacylglycerol kinase regulates tyrosinase expression and function in human melanocytes.Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action.N-methyl-substituted fluorescent DAG-indololactone isomers exhibit dramatic differences in membrane interactions and biological activityStructural Basis for the Failure of the C1 Domain of Ras Guanine Nucleotide Releasing Protein 2 (RasGRP2) to Bind Phorbol Ester with High Affinity.Characterization of the differential roles of the twin C1a and C1b domains of protein kinase C-deltaPolar 3-alkylidene-5-pivaloyloxymethyl-5'-hydroxymethyl-gamma-lactones as protein kinase C ligands and antitumor agentsConformationally constrained analogues of diacylglycerol (DAG). 31. Modulation of the biological properties of diacylgycerol lactones (DAG-lactones) containing rigid-rod acyl groups separated from the core lactone by spacer units of different lengthLipid binding domains: more than simple lipid effectors.Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cδ.Synthesis and biological activities of simplified analogs of the natural PKC ligands, bryostatin-1 and aplysiatoxin.Protein Kinase C Activation as a Potential Therapeutic Strategy in Alzheimer's Disease: Is there a Role for Embryonic Lethal Abnormal Vision-like Proteins?C1 domain-targeted isophthalates as protein kinase C modulators: structure-based design, structure-activity relationships and biological activities.Protein kinase C in cancer: The top five unanswered questions.Protein kinase C: an attractive target for cancer therapy.Modeling studies on the structural determinants for the DAG/phorbol ester binding to C1 domain.Rho GTPase signaling complexes in cell migration and invasion.Importance of the REM (Ras exchange) domain for membrane interactions by RasGRP3.The C1 domain of Vav3, a novel potential therapeutic target.ELAC (3,12-di-O-acetyl-8-O-tigloilingol), a plant-derived lathyrane diterpene, induces subventricular zone neural progenitor cell proliferation through PKCβ activation.Scaffold hopping from (5-hydroxymethyl) isophthalates to multisubstituted pyrimidines diminishes binding affinity to the C1 domain of protein kinase C.Characterization of AJH-836, a DAG-lactone with selectivity for novel PKC isozymes.
P2860
Q27024068-5486281D-F579-452A-AB9E-4B3B5C86AC72Q27683701-654EF209-1F5F-434E-A904-B3AE3B73CCF6Q27690752-DA7372A7-4ADE-4B31-A91D-C7C411627704Q28265620-98BAE4E8-222A-4B63-A4A0-67DAF2DA96F7Q28386247-44B96C10-7676-4E39-85E7-CAC0B87D7DA8Q28478227-201DFDDB-FDE0-49DA-B483-37DB6B195D25Q30500170-8A0C401B-DC40-47C3-9005-6E5C6E830F23Q33744860-68E5E92D-29B4-4104-A5F8-1A8E5306529FQ33850659-9D4E90C0-C1A8-4091-ADDD-6A415D7AA7A7Q33959125-3E2EAEC8-8755-43FA-87A9-C27DE1FCDCAEQ34435702-B2E5FB70-5A08-4712-B620-A72135441AC6Q34571498-521FE101-95E8-4CBA-B4A6-9FC9DBAF1359Q34607325-92463696-B2E8-471E-98E2-EF026F5B08A3Q35027203-15297946-6E96-409D-A8D7-5B780BAB58EAQ35555180-B677CCDD-4231-42CE-91CD-D6B6560D2726Q35856396-A9FA7620-E2BA-4B6F-9AB0-90D5B29D5987Q35921737-59F75057-CD33-4307-90CE-9DFF157EC4CCQ36168212-2351709F-6732-444E-B71D-22EDCD176712Q36376317-6D658A00-1B27-4D1E-8479-7747DECB5DA0Q36412976-B01ED96D-8F77-401D-8510-1D3E89377178Q36557113-F9E91BA4-E926-47AB-B555-585168D3638AQ36880506-9D1A5921-09B1-48C8-990D-2BA9D818AE08Q36987649-234CB828-5C06-4ED2-ABB5-65F638107596Q37036491-7335D703-438B-44D0-AFEC-FD4EEB403910Q37050189-2D4DD0D8-C123-416F-8B23-E0A02910EF82Q37255503-B1AC7BFF-5A6B-4ECA-B917-3CFF24FC7F80Q37325368-CFCF71D2-F3A6-429A-ADC4-BDE2FD6B2252Q38005950-43838686-C4DA-4D7B-8AC9-D779CA116188Q38200047-FDD6172B-A97E-4AF9-9D57-A77EDF5B80EDQ38784086-B6A7F031-2668-4CFA-961F-3E7B42060979Q38940229-C25F0577-EF05-4752-B5F3-DF4A7B09A2A9Q39098659-B5B902EF-DA3E-48A3-BCD4-9EF95E0E3CDFQ41971372-0BFFF445-6ACA-41DB-9242-8BF3FBE8137FQ46231206-B905B381-FAD3-44A8-9709-6C27FA89467BQ47301194-6C2ECB99-FC65-4D50-805B-CFE8316BB197Q47674282-BE30CE90-C9C7-4C92-BB0D-42C4A182DA12Q47777161-6AEFF712-ED0B-4115-8E88-5E6E0A6288B5Q48184130-2E96013B-45EF-41FD-870C-70EA6AF7C358Q52594121-8C5670AD-6C72-4B6F-8ED2-5BC59BBA5642Q52595443-D12F00AC-C457-452D-92C6-73F8B4068218
P2860
Wealth of opportunity - the C1 domain as a target for drug development.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Wealth of opportunity - the C1 domain as a target for drug development.
@ast
Wealth of opportunity - the C1 domain as a target for drug development.
@en
type
label
Wealth of opportunity - the C1 domain as a target for drug development.
@ast
Wealth of opportunity - the C1 domain as a target for drug development.
@en
prefLabel
Wealth of opportunity - the C1 domain as a target for drug development.
@ast
Wealth of opportunity - the C1 domain as a target for drug development.
@en
P2093
P2860
P1433
P1476
Wealth of opportunity - the C1 domain as a target for drug development.
@en
P2093
P M Blumberg
V E Marquez
P2860
P304
P356
10.2174/138945008785132376
P577
2008-08-01T00:00:00Z